Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Epicypher Inc. is prosecuting patents in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action, which is assigned to 1 distinct examiner. This suggests a focused level of activity within the patent office for their epigenetic research applications.
The prosecution is occurring in 1 distinct art unit. HAQ, SHAFIQUL is the busiest examiner for this portfolio, overseeing 1 busiest examiner pending office action. This 1 action is the only pending office action for the entire portfolio. The use of 1 distinct examiner and 1 distinct art unit means the company's current patent strategy is highly concentrated. The 1 pending office action is the focus for their legal representatives. Navigating the requirements of this 1 distinct art unit will be essential for advancing their interests in the biotechnology sector and securing patent protection for their pharmaceutical innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251279 | IMPROVED ASSAYS TO DETECT NUCLEOSOME MODIFICATIONS USING ANTIBODY-TARGETED ENZYME DIGESTION | HAQ, SHAFIQUL | 28d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251279 | IMPROVED ASSAYS TO DETECT NUCLEOSOME MODIFICATIONS USING ANTIBODY-TARGETED ENZYME DIGESTION | HAQ, SHAFIQUL | 28d |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18251279 | IMPROVED ASSAYS TO DETECT NUCLEOSOME MODIFICATIONS USING ANTIBODY-TARGETED ENZYME DIGESTION | HAQ, SHAFIQUL | 1678 | §102§103§112 | Final Rejection | 28d | Pending | May 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial